Who Supplies Ezetimibe to India from PORTUGAL

To import finished pharmaceutical formulations containing Ezetimibe into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41, which includes detailed product information, manufacturing site details, and quality control measures. The Drug Controller General of India (DCGI) evaluates the application to ensure compliance with safety, efficacy, and quality standards. The registration process typically takes several months, depending on the completeness of the application and the need for additional information. For formulations under HS Code 30049099, the manufacturer must provide a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certification, and stability data demonstrating compliance with Indian Pharmacopoeia standards. Additionally, a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare is required for the importation of the drug. The timeline for obtaining import drug registration can vary but generally ranges from 6 to 12 months.

Imported finished pharmaceutical formulations containing Ezetimibe must undergo quality testing at CDSCO-approved laboratories in India. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors perform port inspections to verify the authenticity and quality of the shipments. If a batch fails to meet the required standards, it may be rejected, leading to potential delays or the need for re-exportation.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for the importation of pharmaceutical products, including mandatory import registration and licensing for all imported drugs. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. While there are no specific bilateral agreements between India and Portugal regarding pharmaceutical imports, the general import policies apply uniformly to all foreign suppliers.

India imports finished Ezetimibe formulations primarily due to the demand for branded or patented products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. Despite a robust domestic pharmaceutical industry, certain specialized formulations are sourced from abroad to meet market needs. The market size for Ezetimibe formulations in India is substantial, with a growing patient base requiring cholesterol-lowering medications.

The Basic Customs Duty (BCD) for finished pharmaceutical formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Goods and Services Tax (GST) at 12% is applicable on the landed value, including customs duties. There are no exemptions or concessional rates for imports from Portugal, and no anti-dumping duties are imposed on these products.

India sources finished Ezetimibe formulations from Portugal due to the high quality and compliance with international manufacturing standards. Portuguese manufacturers offer specialized dosage forms and formulations that may not be available from other suppliers. While countries like China, Germany, and the United States also supply Ezetimibe formulations, Portugal's competitive advantage lies in its adherence to stringent quality controls and the ability to meet specific market requirements. Portugal's share in India's Ezetimibe import market is growing, reflecting its increasing competitiveness.

India imports finished Ezetimibe formulations from Portugal due to the availability of specialized dosage forms and formulations not produced domestically. Portuguese manufacturers offer high-quality products that meet international standards, ensuring efficacy and safety. The demand for branded or patented formulations, along with specific dosage forms, drives the need for imports from Portugal.

Compared to other origins like China, Germany, and the United States, Portugal offers competitive pricing and high-quality products. While China may offer lower prices, concerns about quality and regulatory compliance may arise. Germany and the United States provide high-quality products but at higher costs. Portugal's unique advantage lies in its ability to offer quality products at competitive prices, with a focus on meeting specific market needs.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should diversify suppliers, monitor currency trends, stay updated on regulatory changes, conduct regular quality audits, and maintain buffer stocks to manage supply chain disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.
5. 5Regulatory Compliance: Stay informed about changes in import regulations and ensure all necessary documentation is in place.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Submit the application for import registration and license.
3. 3Import License: Obtain the import license from CDSCO.
4. 4No Objection Certificate (NOC): Secure an NOC from the Ministry of Health and Family Welfare.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for